Announcements Trials
Browse Landscape

Phase

Phase 2 32Phase 3 7Phase NA 5Phase 4 5Phase 1 5Phase EARLY_PHASE1 4Phase 2/3 2Phase 1/2 2

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 1

Conditions

Ototoxicity 1Hemangioma, Cavernous, Central Nervous System 1

Interventions

pembrolizumab 410Cyclophosphamide 394Carboplatin 306Gemcitabine 286Nivolumab 276Paclitaxel 274Cisplatin 252Radiotherapy 225Dexamethasone 210Bevacizumab 209fludarabine 192Docetaxel 187Rituximab 183Capecitabine 171Oxaliplatin 158Lenalidomide 157Fluorouracil 152Temozolomide 138Cytarabine 135Etoposide 128Irinotecan 124Cetuximab 123fludarabine phosphate 120Injections 118venetoclax 116Ipilimumab 115Doxorubicin 114Azacitidine 108130-nm albumin-bound paclitaxel 108Pemetrexed 107

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Atorvastatin × Clear all
NCT06553157 2026-01-20

Statins Effect on Incidence of Side Effects of Platinum Based Chemotherapy

Minia University

Phase 1/2 Completed
56 enrolled

Ototoxicity

NCT02603328 2025-08-22

AT CASH EPOC

University of Chicago

Phase 1/2 Completed
80 enrolled 19 charts
CNS

Hemangioma, Cavernous, Central Nervous System

Data powered by HemOnc (CC BY 4.0) Colophon âš¡